Searching for a 1.75mg Wegovy dose? Here's what the schedule actually says

You've heard of 1.75mg Wegovy — where does that figure come from?

Picture this: you're a few months into treatment, you've just moved up to 1.7mg, and you start searching online to learn more about what comes next. The number 1.75mg keeps appearing in forums and comparison sites. It sounds plausible. But it doesn't correspond to anything in the NHS medicines information for semaglutide or the licensed schedule Novo Nordisk published at approval.

The most likely explanation is a rounding error. Some sources approximate 1.7mg as "1.75mg", particularly those drawing on pre-approval trial data or US sources where decimal conventions differ slightly. For UK patients, the pen you receive is labelled 1.7mg, and our page on that dose explains exactly what that means for your treatment. There is no intermediate 1.75mg pen, no off-label half-step, and no clinical guidance supporting one.

If your pen says 1.7mg, you are at the right dose. You can check this in under a minute by looking at the label on your pen's outer carton, which will print the strength clearly alongside the batch number and expiry date. That quick check removes any ambiguity before your next injection.

What the 1.7mg step actually does in the titration sequence

The full Wegovy dose schedule is a deliberate staircase, not an arbitrary set of jumps. Starting at 0.25mg keeps side effects manageable while your body adjusts to semaglutide. Each four-weekly increase builds on that foundation. By the time you reach 1.7mg, most of the early nausea and digestive disruption that people notice at the start of treatment has settled considerably for the majority of patients.

The 1.7mg dose is not a maintenance dose. It is the penultimate step before 2.4mg, which is the standard maintenance level for most patients. That said, some people stay at 1.7mg longer than four weeks if their prescriber decides the increase to 2.4mg should wait, typically because of ongoing side effects or other clinical considerations. That is a perfectly reasonable clinical choice, not a failure of the treatment.

The gap between 1.7mg and 2.4mg is one of the larger jumps in the schedule in absolute terms, which may be why patients notice a difference in appetite suppression when they move up. If you are currently at the 1.7mg step and wondering about the transition, our page on moving from 1.7mg to 2.4mg Wegovy covers what the research and clinical guidance say about that shift.

When a prescriber might pause at this point in the schedule

Not everyone moves through each dose step on the four-week schedule. A prescriber may recommend staying at 1.7mg (or at an earlier dose) if certain patterns appear. Persistent nausea or vomiting that hasn't settled, significant reflux, or any symptoms suggesting the dose is not yet well tolerated are all reasonable grounds for a pause.

There is a common misconception that staying at a lower dose means the treatment isn't working. In practice, the goal is the highest dose you tolerate well, not simply the highest dose available. If you are earlier in the schedule and want to understand the step before 1.7mg, our page covering the 0.75 dose and how it fits into the titration sequence sets out what to expect at that stage. Others will move to 2.4mg and then potentially to 7.2mg, which the MHRA approved as a single-dose pen in April 2026. More detail on what that higher-end option involves is on our page covering the largest available Wegovy dose.

What a prescriber will not do is recommend an unlicensed dose such as 1.75mg. The pens are manufactured at defined strengths, and the titration schedule in the summary of product characteristics sets those steps for good pharmacological reasons. Improvising between them is not how this medicine is used safely.

Sourcing and supervision: what this means for where you get your treatment

Because Wegovy is a prescription-only medicine, the dose you receive must come from a prescriber who has reviewed your clinical picture. That review matters at every step, but particularly at transitions. If you are at 1.7mg and wondering whether to move up, the right path is a clinical conversation, and if you want to know more about the physical device itself before that conversation, our page on the 1.7mg pen covers its design and how to use it correctly.

The GPhC pharmacy register lets you verify any online pharmacy in seconds, and it is worth using before you hand over personal or medical information to any provider. Legitimate services will have a registered premises number, a prescriber involved in every decision, and a clear process for reviewing your progress before approving a dose change.

At nume, every repeat order goes through a same-day clinical review by a GPhC-registered prescriber. No auto-renewals, no algorithmic approvals. If a dose increase is appropriate, that decision is made by a real clinician looking at your specific situation. You can read about how our clinical team approaches these decisions on the clinical team page, and if you have questions about treatment options more broadly, our weight-loss treatment overview sets out what is currently licensed in the UK.

For anyone considering starting treatment or reviewing whether their current plan is the right one, our free consultation is the place to begin. A prescriber will review your details the same day and help you understand which step of the schedule is appropriate for where you are now.